Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

BeiGene - A new comprehensive approach to lung cancer treatment

Single agent IO is the only treatment option for NSCLC with PD-L1 high expression (debate: PRO – M. Reck; CON – T. Mok)

Date

16 Sep 2024

Session

BeiGene - A new comprehensive approach to lung cancer treatment

Topics

Tumour Site

Small Cell Lung Cancer;  Non-Small Cell Lung Cancer

Presenters

Tony S.K. Mok, Martin Reck

Authors

T.S.K. Mok1, M. Reck2

Author affiliations

  • 1 Clinical Oncology Department, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin/HK
  • 2 Thoracic Oncology Department, LungenClinic Grosshansdorf, 22927 - Grosshansdorf/DE

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.